AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00261118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
Study NCT00608972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
Study NCT00608972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
Study NCT00608972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
Study NCT02622230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mianhuahua Flavonoids Tablets
Description: Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)
Study NCT02622230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match with experimental groups
Study NCT01310504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SonoSite Ultrasound
Description: Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
Study NCT04385342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH
Description: Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
Study NCT04385342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HP-hMG
Description: Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
Study NCT04321642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entonox
Description: Entonox gas with mouth piece
Study NCT04321642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Not receive Entonox
Description: Not receive any gas
Study NCT04495894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative Ketorolac
Description: 30 mg ketorolac will be administered intravenously 30 minutes prior to incision.
Study NCT03246581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: inhalation
Study NCT03246581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: inhalation
Study NCT06631599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: The intervention consisted of physical exercise according to various protocols
Study NCT04005521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive intervention
Description: Preventive, structured exercise protocol
Study NCT06631352 — intervention group
Intervention type: OTHER
Intervention: Hepatopancreatoduodenectomy
Description: Pancreatoduodenectomy with liver resection
Study NCT02098031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improving nutrition knowledge among mothers
Study NCT01912326 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Implantation
Description: Implantation of a dual chamber pacemaker
Study NCT02820051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous CO2 monitor
Description: Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.
Study NCT02820051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2 monitor
Description: Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.
Study NCT02820051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
Study NCT02820051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The initial dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
Study NCT02820051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: The starting dose was 2 mg with additional doses of 1 mg if it was necessary.
Study NCT01310504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SonoSite Ultrasound
Description: Paramedics will scan the abdomen and determine it there's fluid within.
Study NCT01316471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Intervention
Description: The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
Study NCT01316471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education: Online Patient Education
Description: The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
Study NCT03048474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab and ipilimumab
Study NCT00718302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antiglide Plate
Description: A plate is placed behind the broken ankle and secured with screws
Study NCT00718302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral Plate
Description: A metal plate is placed to the side of the broken ankle and is secured with screws
Study NCT02820051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: The starting dose was 2 mg with additional doses of 1 mg if it was necessary.
Study NCT02820051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
Study NCT02820051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
Study NCT02232763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 12 weeks of losartan or placebo with crossover to the other
Study NCT02232763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 12 weeks of losartan or placebo with crossover to the other
Study NCT03184545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS
Description: The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.
Study NCT03184545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Standard physical therapy exercises
Study NCT03184545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Standard physical therapy exercises
Study NCT01224678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Given orally
Study NCT01224678 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT04348370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Vaccine
Description: BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.
Study NCT04348370 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.
Study NCT03161522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
Study NCT03161522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive induction chemotherapy
Study NCT03161522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT03161522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
Study NCT03161522 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT00093782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00093782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02373722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mohs Surgery
Description: Undergo Mohs surgery
Study NCT02373722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Watch website application based educational video
Study NCT02373722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive text messages
Study NCT02373722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Watch website application based educational video
Study NCT02373722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Use Fitbit
Study NCT02373722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment
Description: Applied to the wound area
Study NCT02373722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02373722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT00560274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: As prescribed
Study NCT00560274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: As prescribed
Study NCT00560274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta [NeoRecormon]
Description: 30,000 IU sc/week (starting dose)
Study NCT00063323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Study NCT00063323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Study NCT04606017 — intervention group
Intervention type: DRUG
Intervention: Caltrate Pill
Description: VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
Study NCT04485507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature-VR
Description: Viewing 360 degree nature pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
Study NCT04485507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urban-VR
Description: Viewing 360 degree urban pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
Study NCT03607045 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: headless screw
Description: headless screw group
Study NCT03607045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: headless screw
Description: headless screw group
Study NCT00265122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
Study NCT02081768 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90yttrium colloid
Description: 90yttrium colloid will be inserted into a sellar/parasellar cyst
Study NCT02329431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: activation curriculum
Description: psychosocial activation curriculum
Study NCT02329431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: support group
Description: parent directed support group
Study NCT01940562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children \< 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tamsulosin hydrochloride OCAS 0.4 mg
Description: tablet
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tamsulosin hydrochloride OCAS 0.4 mg
Description: tablet
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg
Description: tablet
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg
Description: tablet
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg
Description: tablet
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg
Description: tablet
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg
Description: tablet
Study NCT02456987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung Gear
Description: Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg
Description: tablet
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin hydrochloride OCAS 0.4 mg
Description: tablet
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
Description: tablet
Study NCT01018511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
Description: tablet
Study NCT01021930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)
Description: Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
Study NCT01447914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
Study NCT01447914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic laboratory biomarker analysis
Description: Correlative studies
Study NCT01447914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT01447914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study NCT01843465 — intervention group
Intervention type: OTHER
Intervention: Maneuvers for documenting the disconnection
Study NCT00967369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT00967369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00967369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT00967369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00967369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT00967369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT00967369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Given IV
Study NCT00826761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: One capsule per meal test (high dose or low dose)
Study NCT00826761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsuel every morning
Study NCT03342924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flanker Test and physical fitness test
Description: Socioeconomic status was determined using a trichotomous index. Inbody was used to assess body composition. To assess physical fitness, certain field tests were implemented using devices to quantify precise actions of physicality. Cognitive control was assessed using a computer-based Flanker Task.
Study NCT02706054 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: The patients received an IM injection of saline near the nerve root (periradicular)
Study NCT02706054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: The patients received an IM injection of meloxicam near the nerve root (periradicular)
Study NCT02251041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithrombin-III
Study NCT02251041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Study NCT02251041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apotransferrin
Study NCT02251041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human recombinant erythropoietin
Study NCT02251041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C1-Inhibitor
Study NCT02251041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutathione
Study NCT02251041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfa-tocopherol
Study NCT02251041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Study NCT02251041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoprostenol
Study NCT02251041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride solution